Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,296,689
-$678,967 QoQ
Shares Held
114,491
+18.4% QoQ
Ownership
0.491%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GOLDMAN SACHS GROUP INC holds $10,294,260,512 across 365 Biotechnology names. LYEL ranks #208 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,417,875 | $1,079,677,898 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,300,558 | $1,004,863,129 | |
| 3 | MRNA |
Moderna, Inc.
|
6,603,697 | $335,467,805 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
11,111,591 | $307,791,069 | |
| 5 | PRAX |
Praxis Precision Medicines, Inc.
|
710,734 | $228,991,385 | |
| 6 | INCY |
Incyte Corp
|
2,351,221 | $221,296,919 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
2,185,500 | $212,539,874 | |
| 8 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,965,432 | $170,933,620 |
All Filings in LYEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,296,689 | 114,491 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $2,975,656 | 96,675 | Shares | Defined | 2026-03-25 | |
| No filing history on record for this holder in this stock. | ||||||